About us
Harnessing an innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases.
- Website
-
http://www.minatx.com
External link for MiNA Therapeutics
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 2008
- Specialties
- Gene activation, RNA therapeutics, Liver disease, and Drug discovery
Locations
-
Primary
Get directions
Translation & Innovation Hub
80 Wood Lane
London, W12 0BZ, GB
-
Get directions
Employees at MiNA Therapeutics
-
Deya Corzo, MD, FACMGG
Drug Development Executive; Board-Certified Clinical Geneticist & Pediatrician
-
Bríd Ryan
Senior Vice President of Research at MiNA Therapeutics
-
Konstantinos Vanezis
Senior Research Scientist, MiNA Therapeutics | RNA Activation | Genetic Medicine | Fibrosis | Cardiovascular & Stem Cell Technologies | Translational…
-
Heng Zhu
Senior Patent Agent